{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:01:23Z","timestamp":1793145683391,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s10147-025-02716-2","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T03:52:23Z","timestamp":1739332343000},"page":"674-683","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of dose-dense chemotherapy for early-stage breast cancer under prophylactic pegfilgrastim administration: a systematic review and meta-analysis from clinical practice guidelines for the use of G-CSF 2022"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7068-7117","authenticated-orcid":false,"given":"Takamichi","family":"Yokoe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhiro","family":"Yoshinami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Nozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinori","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Tsuchihashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiki","family":"Ichihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Susumu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munetaka","family":"Takekuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Motohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eishi","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Ochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Uchino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Kamiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinobu","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhisa","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimi","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"issue":"3","key":"2716_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"issue":"15","key":"2716_CR2","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.ejca.2006.05.002","volume":"42","author":"MS Aapro","year":"2006","unstructured":"Aapro MS, Cameron DA, Pettengell R et al (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42(15):2433\u20132453","journal-title":"Eur J Cancer"},{"key":"2716_CR3","first-page":"751","volume-title":"Diseases of the Breast","author":"T Gilewski","year":"1996","unstructured":"Gilewski T, Norton L (1996) Cytokinetics and breast cancer chemotherapy. In: Harris JR, Lippman ME, Morrow M et al (eds) Diseases of the Breast. Lippincott-Raven, Philadelphia, PA, pp 751\u2013768"},{"issue":"8","key":"2716_CR4","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","volume":"21","author":"ML Citron","year":"2003","unstructured":"Citron ML, Berry DA, Cirrincione C et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741\/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21(8):1431\u20131439","journal-title":"J Clin Oncol"},{"issue":"1","key":"2716_CR5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/sj.bjc.6602660","volume":"93","author":"L Del Mastro","year":"2005","unstructured":"Del Mastro L, Bruzzi P, Nicolo G et al (2005) HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients. Br J Cancer 93(1):7\u201314","journal-title":"Br J Cancer"},{"key":"2716_CR6","unstructured":"Morizane T, Yoshida M, Kojimahara N. (2014) Minds Handbook for Clinical Practice Guideline Development 2014. Japan Council for Quality Health Care, Tokyo. https:\/\/minds.jcqhc.or.jp\/s\/developer_manual (in Japanese)."},{"key":"2716_CR7","unstructured":"Kojimahara N, Nakayama T, Morizane T. (2017) Minds Manual for Guideline Development 2017. Japan Council for Quality Health Care, Tokyo. https:\/\/minds.jcqhc.or.jp\/s\/developer_manual (in Japanese)."},{"issue":"7650","key":"2716_CR8","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924\u2013926","journal-title":"BMJ"},{"key":"2716_CR9","unstructured":"Services. USDoHaH. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, Published: November 27, 2017. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50. 2017."},{"key":"2716_CR10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D et al (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16","journal-title":"Trials"},{"issue":"3","key":"2716_CR11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177\u2013188","journal-title":"Control Clin Trials"},{"issue":"7414","key":"2716_CR12","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ et al (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557\u2013560","journal-title":"BMJ"},{"issue":"11","key":"2716_CR13","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539\u20131558","journal-title":"Stat Med"},{"key":"2716_CR14","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700","journal-title":"BMJ"},{"issue":"11","key":"2716_CR15","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1634\/theoncologist.2011-0134","volume":"16","author":"BK Arun","year":"2011","unstructured":"Arun BK, Dhinghra K, Valero V et al (2011) Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results. Oncologist 16(11):1527\u20131534","journal-title":"Oncologist"},{"issue":"7","key":"2716_CR16","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S1470-2045(17)30404-7","volume":"18","author":"D Cameron","year":"2017","unstructured":"Cameron D, Morden JP, Canney P et al (2017) Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK\/05\/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncol 18(7):929\u2013945","journal-title":"Lancet Oncol"},{"issue":"1","key":"2716_CR17","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/cncr.20351","volume":"101","author":"S Culine","year":"2004","unstructured":"Culine S, Romieu G, Fabbro M et al (2004) Reducing the time interval between cycles using standard doses of docetaxel and lenogastrim support: a feasibility study. Cancer 101(1):178\u2013182","journal-title":"Cancer"},{"issue":"6","key":"2716_CR18","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/annonc\/mdf150","volume":"13","author":"RH De Boer","year":"2002","unstructured":"De Boer RH, Eisen TG, Ellis PA et al (2002) A randomised phase II study of conventional versus accelerated infusional chemotherapy with granulocyte colony-stimulating factor support in advanced breast cancer. Ann Oncol 13(6):889\u2013894","journal-title":"Ann Oncol"},{"issue":"9980","key":"2716_CR19","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/S0140-6736(14)62048-1","volume":"385","author":"L Del Mastro","year":"2015","unstructured":"Del Mastro L, De Placido S, Bruzzi P et al (2015) Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 x 2 factorial, randomised phase 3 trial. Lancet 385(9980):1863\u20131872","journal-title":"Lancet"},{"issue":"12","key":"2716_CR20","first-page":"3934","volume":"7","author":"MN Fornier","year":"2001","unstructured":"Fornier MN, Seidman AD, Theodoulou M et al (2001) Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma. Clin Cancer Res 7(12):3934\u20133941","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2716_CR21","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/annonc\/mdm539","volume":"19","author":"G Fountzilas","year":"2008","unstructured":"Fountzilas G, Dafni U, Gogas H et al (2008) Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10\/00. Ann Oncol 19(5):853\u2013860","journal-title":"Ann Oncol"},{"issue":"8","key":"2716_CR22","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1200\/JCO.2001.19.8.2232","volume":"19","author":"G Fountzilas","year":"2001","unstructured":"Fountzilas G, Papadimitriou C, Dafni U et al (2001) Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group. J Clin Oncol 19(8):2232\u20132239","journal-title":"J Clin Oncol"},{"issue":"4","key":"2716_CR23","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3816\/CBC.2002.n.031","volume":"3","author":"C Jackisch","year":"2002","unstructured":"Jackisch C, von Minckwitz G, Eidtmann H et al (2002) Dose-dense biweekly doxorubicin\/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin\/cyclophosphamide\/docetaxel in operable breast cancer: second interim analysis. Clin Breast Cancer 3(4):276\u2013280","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"2716_CR24","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/sj.bjc.6604862","volume":"100","author":"RL Jones","year":"2009","unstructured":"Jones RL, Walsh G, Ashley S et al (2009) A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer. Br J Cancer 100(2):305\u2013310","journal-title":"Br J Cancer"},{"issue":"2","key":"2716_CR25","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.critrevonc.2005.08.009","volume":"58","author":"S Kummel","year":"2006","unstructured":"Kummel S, Krocker J, Kohls A et al (2006) Dose-dense adjuvant chemotherapy for node-positive breast cancer in women 60 years and older: feasibility and tolerability in a subset of patients in a randomized trial. Crit Rev Oncol Hematol 58(2):166\u2013175","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"2716_CR26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3109\/0284186X.2010.535847","volume":"50","author":"S Margolin","year":"2011","unstructured":"Margolin S, Bengtsson NO, Carlsson L et al (2011) A randomised feasibility\/phase II study (SBG 2004\u20131) with dose-dense\/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC\/T versus T, doxorubicin and C (TAC) in node-positive breast cancer. Acta Oncol 50(1):35\u201341","journal-title":"Acta Oncol"},{"issue":"10","key":"2716_CR27","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1093\/annonc\/mdw274","volume":"27","author":"D Mavroudis","year":"2016","unstructured":"Mavroudis D, Matikas A, Malamos N et al (2016) Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). Ann Oncol 27(10):1873\u20131878","journal-title":"Ann Oncol"},{"issue":"17","key":"2716_CR28","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1200\/JCO.2009.24.7643","volume":"28","author":"V Moebus","year":"2010","unstructured":"Moebus V, Jackisch C, Lueck HJ et al (2010) Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 28(17):2874\u20132880","journal-title":"J Clin Oncol"},{"issue":"1","key":"2716_CR29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/annonc\/mdl355","volume":"18","author":"P Piedbois","year":"2007","unstructured":"Piedbois P, Serin D, Priou F et al (2007) Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin\/cyclophosphamide (T\/EC), or the reverse sequence (EC\/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Ann Oncol 18(1):52\u201357","journal-title":"Ann Oncol"},{"issue":"26","key":"2716_CR30","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1200\/JCO.2012.48.1275","volume":"31","author":"SM Swain","year":"2013","unstructured":"Swain SM, Tang G, Geyer CE Jr et al (2013) Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. J Clin Oncol 31(26):3197\u20133204","journal-title":"J Clin Oncol"},{"issue":"5","key":"2716_CR31","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2003.05.135","volume":"21","author":"P Therasse","year":"2003","unstructured":"Therasse P, Mauriac L, Welnicka-Jaskiewicz M et al (2003) Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J Clin Oncol 21(5):843\u2013850","journal-title":"J Clin Oncol"},{"issue":"23","key":"2716_CR32","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/jnci\/dji398","volume":"97","author":"M Venturini","year":"2005","unstructured":"Venturini M, Del Mastro L, Aitini E et al (2005) Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst 97(23):1724\u20131733","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2716_CR33","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/annonc\/mdm438","volume":"19","author":"G von Minckwitz","year":"2008","unstructured":"von Minckwitz G, Kummel S, du Bois A et al (2008) Pegfilgrastim +\/- ciprofloxacin for primary prophylaxis with TAC (docetaxel\/doxorubicin\/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol 19(2):292\u2013298","journal-title":"Ann Oncol"},{"issue":"12","key":"2716_CR34","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1200\/JCO.2005.05.078","volume":"23","author":"G von Minckwitz","year":"2005","unstructured":"von Minckwitz G, Raab G, Caputo A et al (2005) Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 23(12):2676\u20132685","journal-title":"J Clin Oncol"},{"issue":"15","key":"2716_CR35","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1016\/j.ejca.2013.06.012","volume":"49","author":"BE Vriens","year":"2013","unstructured":"Vriens BE, Aarts MJ, de Vries B et al (2013) Doxorubicin\/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer. Eur J Cancer 49(15):3102\u20133110","journal-title":"Eur J Cancer"},{"issue":"1","key":"2716_CR36","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10549-008-9970-z","volume":"114","author":"H Wildiers","year":"2009","unstructured":"Wildiers H, Dirix L, Neven P et al (2009) Delivery of adjuvant sequential dose-dense FEC-Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Res Treat 114(1):103\u2013112","journal-title":"Breast Cancer Res Treat"},{"issue":"10179","key":"2716_CR37","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/S0140-6736(18)33137-4","volume":"393","author":"Early Breast Cancer Trialists' Collaborative G","year":"2019","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative G (2019) Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet 393(10179):1440\u20131452","journal-title":"Lancet"},{"issue":"2","key":"2716_CR38","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10549-023-07015-w","volume":"201","author":"N Shibata","year":"2023","unstructured":"Shibata N, Yoshinami T, Tamaki K et al (2023) Real-world data analysis of perioperative chemotherapy patterns, G-CSF use, and FN status in patients with early breast cancer. Breast Cancer Res Treat 201(2):265\u2013273","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"2716_CR39","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.2002.20.3.727","volume":"20","author":"FA Holmes","year":"2002","unstructured":"Holmes FA, O\u2019Shaughnessy JA, Vukelja S et al (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III\/IV breast cancer. J Clin Oncol 20(3):727\u2013731","journal-title":"J Clin Oncol"},{"issue":"1","key":"2716_CR40","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10549-020-05602-9","volume":"181","author":"Y Brandberg","year":"2020","unstructured":"Brandberg Y, Johansson H, Hellstrom M et al (2020) Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer. Breast Cancer Res Treat 181(1):87\u201396","journal-title":"Breast Cancer Res Treat"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02716-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02716-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02716-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T15:00:02Z","timestamp":1743260402000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02716-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["2716"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02716-2","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]},"assertion":[{"value":"17 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TE.Y. received honoraria from Kyowa-Kirin, Pfizer, Chugai, Eli Lilly, MSD, AstraZeneca and Eisai. Y.O. received honoraria from Daiichi-Sankyo, Pfizer, Chugai, Lilly and Kyowa Kirin. K.T. received honoraria from Ono, Chugai, Taiho and Novartis. E.I. received honoraria from Eli Lilly, and research funding from MSD, Ono, Janssen Pharma and Takeda. Y.M. received honoraria from Ono, MSD, Takeda, Eisai and Bristol Myers Squibb, and research funding from MSD and Ono. S.Y. received research funding from Otsuka. D.M. received honoraria from Janssen, Nippon Shinyaku, Eisai, Mundipharma, Kyowa Kirin, Chugai, Zenyaku, MSD, SymBio, Sanofi, AbbVie, Takeda, Astra Zeneca and Bristol Myers Squibb, and research funding from Biopharma, Novartis, Kyowa Kirin, Ono, Chugai, Janssen, Takeda, Otsuka, Sanofi, Astellas, Bristol Myers Squibb, AbbVie, Eisai, MSD, Taiho and Astra Zeneca. T.M. received honoraria from Astra Zeneca, Chugai and Myriadgenetics. E.B. received honoraria from Chugai, and Daiichi-Sankyo, and research funding from Taiho and Chugai. T.KU. received honoraria from Chugai. T.KI. received honoraria from Sanofi. S.N. received honoraria from Kyowa Kirin. A.S. received honoraria and scholarship donation from Chugai and Taiho. T.T. received honoraria from Daiichi-Sankyo, Chugai and Eli Lilly. Other authors declare that there are no conflicts of interest associated with this manuscript. The other authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors consented to the publication of this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}